Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $14.50.

OBIO has been the topic of several analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, March 12th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Orchestra BioMed in a research report on Thursday. Barclays boosted their price objective on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday. Wall Street Zen upgraded Orchestra BioMed from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings downgraded Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st.

Insider Transactions at Orchestra BioMed

In other Orchestra BioMed news, insider David P. Hochman purchased 10,000 shares of Orchestra BioMed stock in a transaction that occurred on Friday, March 13th. The shares were bought at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the acquisition, the insider directly owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. This trade represents a 0.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Knott David M Jr increased its position in Orchestra BioMed by 1.5% during the 1st quarter. Knott David M Jr now owns 253,651 shares of the company’s stock valued at $1,078,000 after purchasing an additional 3,651 shares during the period. Citadel Advisors LLC increased its position in Orchestra BioMed by 9.2% during the 3rd quarter. Citadel Advisors LLC now owns 54,002 shares of the company’s stock valued at $134,000 after purchasing an additional 4,561 shares during the period. Bank of America Corp DE increased its position in Orchestra BioMed by 35.7% during the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock valued at $58,000 after purchasing an additional 5,678 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Orchestra BioMed during the 4th quarter worth approximately $38,000. Finally, Virtu Financial LLC purchased a new position in shares of Orchestra BioMed during the 4th quarter worth approximately $57,000. 53.20% of the stock is owned by hedge funds and other institutional investors.

Orchestra BioMed Trading Up 1.2%

NASDAQ OBIO opened at $4.11 on Friday. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The company has a current ratio of 7.03, a quick ratio of 6.43 and a debt-to-equity ratio of 0.35. The stock has a 50-day moving average of $4.31 and a 200-day moving average of $4.27. The firm has a market cap of $246.11 million, a PE ratio of -4.24 and a beta of 0.52.

Orchestra BioMed (NASDAQ:OBIO) last released its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.92 million. As a group, sell-side analysts forecast that Orchestra BioMed will post -1.68 EPS for the current year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.